Skip to main content

Advertisement

SpringerLink
Log in

Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Myelofibrosis with myeloid metaplasia is a clonal disorder resulting from proliferation of aberrant hematopoietic progenitors. It can occur either de novo or secondary to an antecedent chronic myeloid disorder such as essential thrombocythemia or polycythemia vera. The only curative option is allogeneic hematopoietic cell trans-plantation, which can result in durable donor engraftment and regression of myelofibrosis in approximately 50% of eligible patients. Unfortunately the median age at presentation is 65 years and many patients have serious comorbidities, so the vast majority of patients are excluded from such an approach. Reduced-intensity conditioning regimens have been shown to result in successful engraftment and resolution of myelofibrosis with less toxicity, although follow-up remains relatively short. Complications such as graft-versus-host disease remain the major barrier to greater success. At present this modality is generally restricted to younger patients with intermediate-to high-risk disease. We provide a current algorithm for incorporating allogeneic transplantation into the management of patients with myelofibrosis. We are hopeful that recent advances in allogeneic transplantation, combined with progress in understanding the molecular pathobiology of chronic myeloproliferative disorders, will lead in the near future to a further refinement of prognostic determinants, new molecular targets to exploit, and therefore a dynamic evolution of the indications for allogeneic transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Tefferi A: Myelofibrosis with myeloid metaplasia [review]. N Engl J Med 2000, 342:1255–1265.

    Article  PubMed  CAS  Google Scholar 

  2. Tefferi A, Deeg HJ: Deciding on transplantation for myelofibrosis: setting the record straight. Mayo Clin Proc 2004, 79:953–954.

    Article  PubMed  Google Scholar 

  3. Mesa RA, Silverstein MN, Jacobsen SJ, et al.: Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976–1995. Am J Hematol 1999, 61:10–15.

    Article  PubMed  CAS  Google Scholar 

  4. Reilly JT: Idiopathic myelofibrosis: pathogenesis, natural history and management [review]. Blood Rev 1997, 11:233–242.

    Article  PubMed  CAS  Google Scholar 

  5. Rozman C, Giralt M, Feliu E, et al.: Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991, 67:2658–2663.

    Article  PubMed  CAS  Google Scholar 

  6. Dingli D, Schwager SM, Mesa RA, et al.: Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system. Cancer 2006, 106:623–630.

    Article  PubMed  Google Scholar 

  7. Visani G, Finelli C, Castelli U, et al.: Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 1990, 75:4–9.

    PubMed  CAS  Google Scholar 

  8. Dupriez B, Morel P, Demory JL, et al.: Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996, 88:1013–1018.

    PubMed  CAS  Google Scholar 

  9. Cervantes F, Pereira A, Esteve J, et al.: Identification of “short-lived” and “long-lived” patients at presentation of idiopathic myelofibrosis. Br J Haematol 1997, 97:635–640.

    Article  PubMed  CAS  Google Scholar 

  10. Mesa RA, Steensma DP, Pardanani A, et al.: A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003, 101:2534–2541.

    Article  PubMed  CAS  Google Scholar 

  11. Tefferi A, Cortes J, Verstovsek S, et al.: Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006, 108:1158–1164.

    Article  PubMed  CAS  Google Scholar 

  12. Kralovics R, Passamonti F, Buser AS, et al.: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779–1790.

    Article  PubMed  CAS  Google Scholar 

  13. Baxter EJ, Scott LM, Campbell PJ, et al.: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054–1061. [Published erratum appears in Lancet 2005, 366:122.].

    PubMed  CAS  Google Scholar 

  14. Tefferi A, Sirhan S, Lasho TL, et al.: Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol 2005, 131:166–171.

    Article  PubMed  CAS  Google Scholar 

  15. James C, Ugo V, Le Couedic JP, et al.: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144–1148.

    Article  PubMed  CAS  Google Scholar 

  16. Levine RL, Wadleigh M, Cools J, et al.: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387–397.

    Article  PubMed  CAS  Google Scholar 

  17. Tefferi A, Dingli D, Li CY, Dewald GW: Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia. Cancer 2005, 104:1656–1660.

    Article  PubMed  CAS  Google Scholar 

  18. Dingli D, Schwager SM, Mesa RA, et al.: Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Cancer 2006, 106:1985–1989.

    Article  PubMed  Google Scholar 

  19. Cutler CS, Lee SJ, Greenberg P, et al.: A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004, 104:579–585.

    Article  PubMed  CAS  Google Scholar 

  20. Mesa RA, Elliott MA, Schroeder G, Tefferi A: Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc 2004, 79:883–889.

    PubMed  CAS  Google Scholar 

  21. Lu X, Levine R, Tong W, et al.: Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A 2005, 102:18962–18967.

    Article  PubMed  CAS  Google Scholar 

  22. Parganas E, Wang D, Stravopodis D, et al.: Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998, 93:385–395.

    Article  PubMed  CAS  Google Scholar 

  23. Neubauer H, Cumano A, Muller M, et al.: Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998, 93:397–409.

    Article  PubMed  CAS  Google Scholar 

  24. Wernig G, Mercher T, Okabe R, et al.: Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006, 107:4274–4281.

    Article  PubMed  CAS  Google Scholar 

  25. Anderson JE, Sale G, Appelbaum FR, et al.: Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol 1997, 98:1010–1016.

    Article  PubMed  CAS  Google Scholar 

  26. Rajantie J, Sale GE, Deeg HJ, et al.: Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation. Blood 1986, 67:1693–1697.

    PubMed  CAS  Google Scholar 

  27. Guardiola P, Anderson JE, Bandini G, et al.: Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999, 93:2831–2838.

    PubMed  CAS  Google Scholar 

  28. Guardiola P, Esperou H, Cazals-Hatem D, et al.: Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. French Society of Bone Marrow Transplantation. Br J Haematol 1997, 98:1004–1009.

    Article  PubMed  CAS  Google Scholar 

  29. Soll E, Massumoto C, Clift RA, et al.: Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment. Blood 1995, 86:4667–4673.

    PubMed  CAS  Google Scholar 

  30. Tefferi A, Mesa RA, Nagorney DM, et al.: Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000, 95:2226–2233.

    PubMed  CAS  Google Scholar 

  31. Li Z, Gooley T, Applebaum FR, Deeg HJ: Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. Blood 2001, 97:2180–2181.

    Article  PubMed  CAS  Google Scholar 

  32. Przepiorka D, Giralt S, Khouri I, et al.: Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases [review]. Am J Hematol 1998, 57:24–28.

    Article  PubMed  CAS  Google Scholar 

  33. Deeg HJ, Gooley TA, Flowers ME, et al.: Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003, 102:3912–3918.

    Article  PubMed  CAS  Google Scholar 

  34. Guardiola P, Anderson JE, Gluckman E: Myelofibrosis with myeloid metaplasia [letter]. N Engl J Med 2000, 343:659.

    Article  PubMed  CAS  Google Scholar 

  35. Deeg HJ, Appelbaum FR: Stem-cell transplantation for myelofibrosis [letter]. N Engl J Med 2001, 344:775–776.

    Article  PubMed  CAS  Google Scholar 

  36. Daly A, Song K, Nevill T, et al.: Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant 2003, 32:35–40.

    Article  PubMed  CAS  Google Scholar 

  37. Ditschkowski M, Beelen DW, Trenschel R, et al.: Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplant 2004, 34:807–813.

    Article  PubMed  CAS  Google Scholar 

  38. Anderson JE, Tefferi A, Craig F, et al.: Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood 2001, 98:586–593.

    Article  PubMed  CAS  Google Scholar 

  39. Richard S, Isola L, Scigliano E, et al.: Syngeneic stem cell transplant for spent-phase polycythaemia vera: eradication of myelofibrosis and restoration of normal haematopoiesis. Br J Haematol 2002, 117:245–246.

    Article  PubMed  Google Scholar 

  40. Byrne JL, Beshti H, Clark D, et al.: Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a “graft vs. myelofibrosis” effect. Br J Haematol 2000, 108:430–433.

    Article  PubMed  CAS  Google Scholar 

  41. Cervantes F, Rovira M, Urbano-Ispizua A, et al.: Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplant 2000, 26:697–699.

    Article  PubMed  CAS  Google Scholar 

  42. Devine SM, Hoffman R, Verma A, et al.: Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002, 99:2255–2258.

    Article  PubMed  CAS  Google Scholar 

  43. van Besien K, Deeg HJ: Hematopoietic stem cell transplantation for myelofibrosis. Semin Oncol 2005, 32:414–421.

    Article  PubMed  Google Scholar 

  44. Hessling J, Kroger N, Werner M, et al.: Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002, 119:769–772.

    Article  PubMed  Google Scholar 

  45. Rondelli D, Barosi G, Bacigalupo A, et al.: Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate-or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005, 105:4115–4119.

    Article  PubMed  CAS  Google Scholar 

  46. Rondelli D, Barosi G, Bacigalupo A, et al.: Allogeneic HSCT with reduced intensity conditioning regimens in high risk patients with myelofibrosis [abstract]. Biol Blood Marrow Transplant 2004, 10:12. Abstract 16.

    Article  Google Scholar 

  47. Kroger N, Zabelina T, Schieder H, et al.: Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 2005, 128:690–697.

    Article  PubMed  CAS  Google Scholar 

  48. Sorror ML, Maris MB, Storb R, et al.: Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912–2919.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    William J. Hogan MD

Authors
  1. William J. Hogan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark R. Litzow MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ayalew Tefferi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William J. Hogan MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hogan, W.J., Litzow, M.R. & Tefferi, A. Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia. Curr Hematol Malig Rep 2, 34–42 (2007). https://doi.org/10.1007/s11899-007-0005-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-007-0005-3

Keywords

Search

Navigation